Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 6/20 | 0.53 |
| ▸ | PRKACA | P17612 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ELOVL1 | Q9BW60 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | WNT3A | P56704 | 4/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436508 | 0.89 | ROCK1 (0.53) | ROCK1PRKACAMEN1KMT2AELOVL1 | |
| SCHEMBL13213570 | 0.88 | ELOVL1 (0.52) | ROCK1PRKACAMEN1KMT2AELOVL1 | |
| SCHEMBL437330 | 0.87 | ROCK1 (0.57) | ROCK1PRKACAMEN1KMT2AELOVL1 | |
| SCHEMBL436513 | 0.85 | ROCK1 (0.58) | ROCK1PRKACAMEN1KMT2AELOVL1 | |
| SCHEMBL438723 | 0.83 | ROCK1 (0.56) | ROCK1PRKACAMEN1KMT2AELOVL1 | |
| SCHEMBL439246 | 0.83 | WNT3A (0.58) | ROCK1PRKACAMEN1KMT2AELOVL1 | |
| SCHEMBL438722 | 0.81 | CYP3A4 (0.57) | ROCK1PRKACAMEN1KMT2AELOVL1 | |
| SCHEMBL436506 | 0.80 | ROCK1 (0.53) | ROCK1PRKACAMEN1KMT2AELOVL1 | |
| SCHEMBL439513 | 0.79 | ELOVL1 (0.62) | ROCK1PRKACAMEN1KMT2AELOVL1 | |
| SCHEMBL437415 | 0.79 | ROCK1 (0.62) | ROCK1PRKACAMEN1KMT2AELOVL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278306-B2 | C-met protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278306-B2 | C-met protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120065213-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065213-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058271-B2 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058271-B2 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2032562-B1 | SELECTIVE INHIBITORS OF ROCK PROTEIN KINASE AND USES THEREOF | VERTEX PHARMA (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2007133622-A2 | SELECTIVE INHIBITORS OF ROCK PROTEIN KINASE AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270386-A1 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20070270386-A1 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270386-A1 | Selective inhibitors of rock protein kinase and uses thereof | ROCK1, ROCK2, MYLK | ROCK1 1/4885PRKACA 99/4885MEN1 1248/4885 |
| US-20120065213-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, MYLK | ROCK1 4/4885PRKACA 61/4885MEN1 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.